medigraphic.com
ISSN 0016-3813 (Print)

2009, Number 4

<< Back Next >>

Gac Med Mex 2009; 145 (4)

IV. Diseño de estrategias para disminuir los daños a la salud asociados a hipertensión arterial

Alcocer L

Language: Spanish
References: 19
Page: 299-303
PDF size: 50.96 Kb.


ABSTRACT

Inadequate levels of arterial pressure constitute a serious health risk for adults and are the main source of decreased quality of life indicators especially among middle income countries such as Mexico. In addition, they also imply a great economic burden on families and the economy as a whole. The treatment and prevention of arterial hypertension have demonstrated a direct and clear benefit in reducing disease complications under a cost effective scheme. These reasons justify the development and implementation of control strategies at the community level which include: prevention of overweight dyslipidemia and diabetes, healthy lifestyles and decreasing smoking. Main target groups include at risk subjects that will be determined according to pressure levels and risk. Compliance and treatment adherence will help fight this global epidemic.


REFERENCES

  1. Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: How many lives can we save? Lancet 2005;366:1578-1582.

  2. World Health Organization. Preventing chronic diseases: a vital investment. WHO Global Report. Geneva: World Health Organization; 2005. Disponible en http://www.who.int/chp/chronic_disease_report/contents/en/index.html

  3. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007;370:1929-1938.

  4. Mathers CD, Lopez AD, Stein C, Fat DM, Rao C. Deaths and disease burden by cause: global burden of disease estimates for 2001 by World Bank Country Groups. Bethesda, MD: WHO/World Bank/ Fogarty International Center/US National Institutes of Health/DCPP Working Papers Series No. 18, Second Project on Disease Control Priorities in Developing Countries; 2005. Disponible en http://www.dcp2.org/file/33/wp18.pdf

  5. Secretaría de Salud. Encuesta Nacional de Salud y Nutrición 2006 (ENSANut 2006). Cuernavaca, Morelos, México: Secretaría de Salud/ Instituto Nacional de Salud Pública; 2005. Disponible en http://www.insp.mx/ensanut/

  6. Chobanian AV; the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-2572.

  7. World Health Organization. The World Health Report. 2002: reducing risks, promoting healthy life. Geneva: World Health Organization; 2002. Disponible en http://www.who.int/chp/chronic_disease_report/contents/en/index.html

  8. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155(7):701-709.

  9. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.

  10. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419. [Erratum BMJ 2003;327:586.]

  11. Pan American Health Organization. (2006). FACTS sheet. Assessing the economic impact of obesity and associated chronic diseases: Latin America and the Caribbean. Disponible en http://www.dpaslac.org/uploads/1164748750.pdf

  12. Arredondo A, Zúñiga A. Epidemiologic changes and economic burden of hypertension in Latin America: evidence from Mexico. Am J Hypertens 2006;19:553-559.

  13. Joshi R, Jan S, Wu. Mac Mahon S. Global inequalities in access to cardiovascular health care. J Am Coll Cardiol 2008;52:1817-1825.

  14. Baltussen R, Adam T, Tan-Torres T, Hutubessy R, Acharya A, Evans D, et al. Generalized cost-effectiveness analysis: a guide. Geneva, Switzerland: Global Programme on Evidence for Health Policy, World Health Organization; 2002. Disponible en http://www.who.int/choice/publications/p_2003_generalised_cea.pdf

  15. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al. For the National High Blood Pressure Education Program Coordinating Committee. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 2002;288:1882-1888.

  16. Murray CJ, Lauer JA, Hutubessy RC, Niessen L. Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovasculardisease risk. Lancet 2003;361:717-725.

  17. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006;368:679-686.

  18. Schargrodsky H, Hernández-Hernández R, Champagne BM, Silva H, Vinueza R, Silva Aycaguer L, et al. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med 2008;121:58-65.

  19. Bautista LE, Orostegui M, Vera LM, Prada G, Orozco L, Herrán O. Prevalence and impact of cardiovascular risk factors in Bucaramanga, Colombia: results from the Countrywide Integrated Noncommunicable Disease Intervention Programme (CINDI/CARMEN) baseline survey. Eur J Cardiovasc Prev Rehabil 2006;13:769-775.




2020     |     www.medigraphic.com